OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Cancer is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
The impossibility of mortality evaluation of skin cancer screening in Germany based on health insurance data: a case–control study	404
Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome	250
Onco-functional outcome after resection for eloquent glioblastoma (OFO): A propensity-score matched analysis of an international, multicentre, cohort study	183
Gut microbiome and immune checkpoint inhibitor toxicity	173
Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database	165
Nivolumab and hypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial	144
Editorial Board	144
Total neoadjuvant treatment, non-operative management and radiotherapy-free strategies: New approaches for the management of proficient mismatch repair/microsatellite stable locally advanced rectal ca	142
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model	142
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONA	142
Editorial Board	133
Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial	130
“Symptomatic” melanoma brain metastases: A call for clear definitions and adoption of standardized tools	125
The development of an archive of patient-reported outcome measures (PROMs) in oncology: The Italian PRO4All project	120
Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer	107
Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial	106
Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab	99
Validation and development of a refined M1 category for nasopharyngeal carcinoma based on the version-nine of AJCC/UICC TNM staging system in the immunotherapy era: A multicenter cohort study	96
Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma	95
Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes	93
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies	92
Preclinical activity for TPX-4589 (LM-302), an antibody-drug conjugate targeting tight junction protein CLDN18.2 in solid tumors	90
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial	90
Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study	87
Artificial intelligence-assisted probability scoring for differentiation of early mycosis fungoides and benign inflammatory dermatoses on H&E stained pathology slides of skin biopsies	84

Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy	82
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis	82
Cancer and immunotherapy: a role for microbiota composition	80
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies	80
Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers	79
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizum	77
Troponin increase during immunotherapy: Not always myocarditis	75
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical tria	75
A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands	73
Gene expression-based prediction of pazopanib efficacy in sarcoma	69
Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis	69
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS	68
The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer	67
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial	66
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inh	65
Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: A population-based study	64
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma	63
Kidney function assessment for eligibility in clinical cancer trials – Data from the European Organisation for Research and Treatment of Cancer	62
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma	62
Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting	60
Editorial Board	60
Letter Re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma	60
Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB	58
Editorial Board	58
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer	58
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression	57
Editorial Board	56
Association of a novel BRCA2 mutation with prostate cancer risk further supports germline genetic testing	56
False-Negative Rates Between Pathological Lymph Node Status Between Ductal and Lobular Breast Cancer: A Retrospective Cohort Study of 83,152 Patients	56
Surgical choices and complications in elderly women: a single center retrospective analysis in frail vs non frail breast cancer patients	55
Spatial Immunophenotyping Identifies Differential Infiltration of Immunosuppressive Subsets in Tumor Stroma and Invasive Margin and PDL1 expression in Inflammatory and non-Inflammatory Breast Cancer P	55